A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

After a screening period of up to 29 days prior to study drug administration, eligible
participants will be residential for a single period of 6 days/5 nights in Part 1 and 19
days/18 nights in Part 2 . Participants will be admitted to the clinical unit on day 2.

Inclusion Criteria:

- Subject has a body mass index (BMI) range of 18.5 to 32.0 kg/m2, inclusive, and weighs
at least 50 kg at screening.

- Female subject must either:

- Be of nonchildbearing potential: Postmenopausal (defined as at least 1 year
without any menses for which there is no other obvious pathological or
physiological cause) prior to screening, or documented surgically sterile (e.g.,
hysterectomy, bilateral salpingectomy, bilateral oophorectomy)

- Or, if of childbearing potential, agree not to try to become pregnant during the
study and for 28 days after the final study drug administration, and have a
negative blood/urine pregnancy test at screening and day -2, and if
heterosexually active, agree to consistently use 1 form of highly effective birth
control starting at screening and throughout the study period and for 28 days
after the final study drug administration.

- Female subject must agree not to breastfeed starting at screening and throughout the
study period, and for 28 days after the final study drug administration.

- Female subject must not donate ova starting at screening and throughout the study
period, and for 28 days after the final study drug administration.

- A sexually active male subject with female partner(s) who are of childbearing
potential is eligible if:

- Agree to use a male condom starting at screening and continue throughout study
treatment and for 90 days after the final study drug administration. If the male
subject has not had a vasectomy or is not sterile as defined below the subject's
female partner(s) is utilizing 1 form of highly effective birth control starting
at screening and continue throughout study treatment and for 90 days after the
final study drug administration.

- Male subject must not donate sperm starting at screening and throughout the study
period, and for 90 days after the final study drug administration.

- Male subject with a pregnant or breastfeeding partner(s) must agree to remain
abstinent or use a condom for the duration of the pregnancy or time partner is
breastfeeding throughout the study period and for 28 days after the final study drug
administration.

- Subject agrees not to participate in another interventional study while participating
in the present clinical study, defined as signing the informed consent form until
completion of the last study visit.

Exclusion Criteria:

- Subject participated in any clinical study or has been treated with any
investigational drugs within 28 days prior to screening.

- Subject has any condition which makes the subject unsuitable for clinical study
participation.

- Female subject who has been pregnant within 6 months prior to screening assessment or
breast feeding within 3 months prior to screening.

- Subject has a known or suspected hypersensitivity to MA-0211, or any components of the
formulation used.

- Subject has had previous exposure with MA-0211.

- Subject has any of the liver function tests (aspartate aminotransferase [AST], alanine
amino-transferase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT]
and total bilirubin [TBL]) above the upper limit of normal at day -2. In such a case,
the assessment may be repeated once.

- Subject has total creatine kinase greater than 1.5 times the upper limit of normal or
troponin I above the upper limit of normal at day -2.

- Subject has any clinically significant history of allergic conditions (including drug
allergies, asthma, eczema or anaphylactic reactions, but excluding untreated,
asymptomatic, seasonal allergies) prior to study drug administration.

- Subject has any history or evidence of any clinically significant cardiovascular,
gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic,
pulmonary, neurologic, psychiatric, dermatologic, renal and/or other major disease or
malignancy.

- Subject has/had febrile illness or symptomatic, viral, bacterial (including upper
respiratory infection), or fungal (noncutaneous) infection within 1 week prior to (day
-2).

- Subject has any clinically significant abnormality following the investigator's review
of the physical examination, ECG and protocol-defined clinical safety laboratory tests
at screening or day 2.

- Subject has a mean heart rate < 45 or > 90 beats per minute; mean Systolic blood
pressure (SBP) > 140 mmHg; mean diastolic blood pressure (DBP) > 90 mmHg at day -2
(vital signs measurements taken in triplicate after subject has been resting in supine
position for 5 minutes; heart rate will be measured automatically). If the mean heart
rate, SBP or DBP exceeds the limits above, 1 additional triplicate can be taken (day
-2).

- Subject has a mean QT interval using Fridericia's correction (QTcF) > 430ms (for
males) and >450ms (for females) at day 2 or if the subject has any family history of
long QT syndrome (LQTS). If the mean QTcF exceeds the limits above, 1 additional
triplicate ECG can be taken (day -2).

- Subject has used any prescribed or nonprescribed drugs (including vitamins, calcium
and iron supplements, natural and herbal remedies [e.g., St. John's Wort]) in the 2
weeks (or 5 elimination half-lives, whichever is longer) prior to study drug
administration, except for occasional use of acetaminophen (up to 2 g/day [prn]). In
addition, subject has used any peroxisome proliferator-activated receptor (PPAR)
ligands such as fibrates and thiazolidinediones in the 4 weeks prior to day -2.

- Subject has smoked or has used tobacco-containing products and nicotine or nicotine
containing products in the past 6 months prior to screening.

- Subject has a history of consuming more than 14 units of alcoholic beverages per week
within 6 months prior to screening or has a history of alcoholism or drug/chemical/
substance abuse within the past 2 years prior to screening (Note: 1 unit = 12 ounces
of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor) or the subject tests
positive for alcohol or drugs of abuse at screening or day -2 (amphetamines,
barbiturates, benzodiazepines, cannabinoids, cocaine, and opiates).

- Subject has used any drugs of abuse within 3 months prior to day -2.

- Subject has used any inducer of metabolism (e.g., barbiturates, rifampin) in the 3
month prior to day -2.

- Subject has had significant blood loss, donated 1 unit (500 mL) of blood or more, or
received a transfusion of any blood or blood products within 60 days or donated plasma
within 7 days prior to day -2.

- Subject has a positive serology test for hepatitis B surface antigen (HBsAg) and
hepatitis B core antibodies (anti-HBc), hepatitis A virus antibodies (immunoglobulin
M), hepatitis C virus antibodies (anti-HCV) or antibodies to human immunodeficiency
virus (HIV) type 1 and/or type 2 at screening.

- Subject anticipates an inability to abstain from caffeine-, xanthine- or
grapefruit/Seville orange containing products from at least 24 hours (longer for
grapefruit/Seville orange containing products: 72 hours) before screening, and from at
least 24 hours (longer for grapefruit/Seville orange containing products: 72 hours)
before admission to the clinical unit on day -2 up to and including the End of Study
Visit (ESV).

- Subject is an employee of the Astellas Group or Clinical Research Organization (CRO).